Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Taking Our Hands Off the Wheel.

Tempero M.

J Natl Compr Canc Netw. 2020 Mar;18(3):221. doi: 10.6004/jnccn.2020.0013. No abstract available.

PMID:
32135519
2.

Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review.

Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY.

Pancreas. 2020 Mar;49(3):393-407. doi: 10.1097/MPA.0000000000001507.

3.

Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma.

Sinha M, Griffith M, Betts C, Choe G, Sivagnanam S, Cheung A, Tamaki W, Liu E, Sudduth-Klinger J, Vaccaro G, Lopez C, Fong L, Coussens L, Tempero M.

Ann Oncol. 2019 Jul;30 Suppl 4:iv40. doi: 10.1093/annonc/mdz155.145. Epub 2019 Dec 4. No abstract available.

4.

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes.

Reni M, Riess H, O'Reilly E, Santoro A, Park J, Bekaii-Saab T, Tempero M, Shan Y, Macarulla T, Van Cutsem E, Noel M, Berlin J, Biankin A, Dhani N, Frassineti G, Goldstein D, Romano A, Bruchec YL, Philip P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154. Epub 2019 Dec 4. No abstract available.

5.

Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study.

Tempero M, Oh D, Macarulla T, Reni M, Van Cutsem E, Hendifar A, Waldschmidt D, Starling N, Bachet J, Chang H, Maurel J, Lonardi S, Coussens L, Fong L, Tsao L, Cole G Jr, James D, Tabernero J.

Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. No abstract available.

6.

Analysis of patient screening in the phase III, international, randomized, open-label APACT trial.

Reni M, Winter J, Tortora G, Pelzer U, Riess H, Chang H, O'Reilly E, Oh D, Diaz IA, Milella M, Bendell J, Garlipp B, Tempero M, Macarulla T, Van Cutsem E, Berlin J, Goldstein D, Lu B, Jeanes J, Philip P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv110. doi: 10.1093/annonc/mdz156. Epub 2019 Dec 4. No abstract available.

7.

It's About Time!

Tempero M.

J Natl Compr Canc Netw. 2020 Feb;18(2):115. doi: 10.6004/jnccn.2020.0008. No abstract available.

PMID:
32023523
8.

This Time I Mean It!

Tempero M.

J Natl Compr Canc Netw. 2020 Jan;18(1):1. doi: 10.6004/jnccn.2020.0003. No abstract available.

PMID:
31910382
9.

Santa, Can You Hear Me?

Tempero M.

J Natl Compr Canc Netw. 2019 Dec;17(12):1455. doi: 10.6004/jnccn.2019.0060. No abstract available.

PMID:
31805531
10.

Giving Thanks.

Tempero M.

J Natl Compr Canc Netw. 2019 Nov 1;17(11):1267. doi: 10.6004/jnccn.2019.0055. No abstract available.

PMID:
31693979
11.

CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.

Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA.

Am J Clin Oncol. 2019 Dec;42(12):898-902. doi: 10.1097/COC.0000000000000620.

PMID:
31634155
12.

My Summer Vacation.

Tempero M.

J Natl Compr Canc Netw. 2019 Oct 1;17(10):1147. doi: 10.6004/jnccn.2019.0050. No abstract available.

PMID:
31590150
13.

We All Own This!

Tempero M.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1021. doi: 10.6004/jnccn.2019.0045. No abstract available.

PMID:
31487675
14.

Managing Expectations.

Tempero M.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):893. doi: 10.6004/jnccn.2019.0040. No abstract available.

PMID:
31390589
15.

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A.

J Clin Oncol. 2020 Feb 10;38(5):496-520. doi: 10.1200/JCO.19.01461. Epub 2019 Aug 5.

PMID:
31381464
16.

Taking the Mountain to Muhammad.

Tempero M.

J Natl Compr Canc Netw. 2019 Jul 1;17(7):767. doi: 10.6004/jnccn.2019.0035. No abstract available.

PMID:
31319392
17.

Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.

Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA.

Pancreas. 2019 Aug;48(7):927-930. doi: 10.1097/MPA.0000000000001354.

PMID:
31268983
18.

Tackling Cost: A Prescription for Spending Wisely.

Tempero M.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):633. doi: 10.6004/jnccn.2019.0030. No abstract available.

PMID:
31200360
19.

NCCN Guidelines Updates: Pancreatic Cancer.

Tempero MA.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):603-605. doi: 10.6004/jnccn.2019.5007.

PMID:
31117041
20.

Finding Room for Success.

Tempero M.

J Natl Compr Canc Netw. 2019 May 1;17(5):407. doi: 10.6004/jnccn.2019.0025. No abstract available.

PMID:
31085761
21.

The Time Has Come!

Tempero M.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):295. doi: 10.6004/jnccn.2019.0020. No abstract available.

PMID:
30959464
22.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
23.

Kids, There's an App for That!

Tempero M.

J Natl Compr Canc Netw. 2019 Feb;17(2):101. doi: 10.6004/jnccn.2019.0010. No abstract available.

PMID:
30787121
24.

New Year, New Look!

Tempero M.

J Natl Compr Canc Netw. 2019 Jan;17(1):1. doi: 10.6004/jnccn.2019.0003. No abstract available.

PMID:
30659122
25.

An Oncologist's Letter to Santa: Bring Me Drugs!

Tempero M.

J Natl Compr Canc Netw. 2018 Dec;16(12):1411. doi: 10.6004/jnccn.2018.0090. No abstract available.

PMID:
30545986
26.

I'm Conflicted. Are You?

Tempero M.

J Natl Compr Canc Netw. 2018 Nov;16(11):1273. doi: 10.6004/jnccn.2018.0085. No abstract available.

PMID:
30442729
27.

One Size Fits All? Really?

Tempero M.

J Natl Compr Canc Netw. 2018 Oct;16(10):1161. doi: 10.6004/jnccn.2018.0080. No abstract available.

PMID:
30323084
28.

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.

Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.

Fam Cancer. 2019 Apr;18(2):241-251. doi: 10.1007/s10689-018-0106-2.

PMID:
30267352
29.

Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?

Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE.

Am J Surg Pathol. 2019 Mar;43(3):334-340. doi: 10.1097/PAS.0000000000001152.

PMID:
30211728
30.

Getting What You Pay For: Finding Value in Cancer Care.

Tempero M.

J Natl Compr Canc Netw. 2018 Sep;16(9):1031. doi: 10.6004/jnccn.2018.0077. No abstract available.

PMID:
30181413
31.

Notes From the Other Side.

Tempero M.

J Natl Compr Canc Netw. 2018 Aug;16(8):921-922. doi: 10.6004/jnccn.2018.0068. No abstract available.

PMID:
30099366
32.

Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.

Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA.

AJR Am J Roentgenol. 2018 Nov;211(5):1010-1019. doi: 10.2214/AJR.18.19602. Epub 2018 Jul 31.

PMID:
30063366
33.

Genomic Medicine Takes the Stage, Again!

Tempero M.

J Natl Compr Canc Netw. 2018 Jul;16(7):795. doi: 10.6004/jnccn.2018.0063. No abstract available.

PMID:
30006420
34.

Movin' On Up!

Tempero M.

J Natl Compr Canc Netw. 2018 Jun;16(6):675. doi: 10.6004/jnccn.2018.0057. No abstract available.

PMID:
29891517
35.

Getting Into the Weeds.

Tempero M.

J Natl Compr Canc Netw. 2018 May;16(5):457. doi: 10.6004/jnccn.2018.0027. No abstract available.

PMID:
29752317
36.

Standing Together or Alone.

Tempero M.

J Natl Compr Canc Netw. 2018 Apr;16(4):341. doi: 10.6004/jnccn.2018.0022. No abstract available.

PMID:
29632051
37.

Molecular Diagnostics: Another Battle Brewing.

Tempero M.

J Natl Compr Canc Netw. 2018 Mar;16(3):225. doi: w10.6004/jnccn.2018.0015. No abstract available.

PMID:
29523658
38.

Extending Our Reach-Will Telemedicine Get Us There?

Tempero M.

J Natl Compr Canc Netw. 2018 Feb;16(2):107. doi: 10.6004/jnccn.2018.0008. No abstract available.

PMID:
29439170
39.

Revisiting New Year's Resolutions.

Tempero M.

J Natl Compr Canc Netw. 2018 Jan;16(1):1. doi: 10.6004/jnccn.2018.0003. No abstract available.

PMID:
29295874
40.

HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.

Doherty GJ, Tempero M, Corrie PG.

Future Oncol. 2018 Jan;14(1):13-22. doi: 10.2217/fon-2017-0338. Epub 2017 Oct 23.

PMID:
29235360
41.

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS.

Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17.

42.

It's About Time!

Tempero M.

J Natl Compr Canc Netw. 2017 Dec;15(12):1443. doi: 10.6004/jnccn.2017.0177. No abstract available.

PMID:
29223979
43.

Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies.

Tempero MA.

Cancer J. 2017 Nov/Dec;23(6):309. doi: 10.1097/PPO.0000000000000295. Review. No abstract available.

PMID:
29189324
44.

Who's Watching the Kids?

Tempero M.

J Natl Compr Canc Netw. 2017 Nov;15(11):1289. doi: 10.6004/jnccn.2017.0170. No abstract available.

PMID:
29118220
45.

Serving "a la CAR-T": Value-Based Pricing and Gene Therapy.

Tempero M.

J Natl Compr Canc Netw. 2017 Oct;15(10):1179. doi: 10.6004/jnccn.2017.0162. No abstract available.

PMID:
28982741
46.

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.

Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS 4th, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC.

Oncologist. 2017 Dec;22(12):1427-e129. doi: 10.1634/theoncologist.2017-0066. Epub 2017 Sep 21.

47.

Your Genes: Getting the Best Fit.

Tempero M.

J Natl Compr Canc Netw. 2017 Sep;15(9):1083. doi: 10.6004/jnccn.2017.0152. No abstract available.

PMID:
28874592
48.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
49.

When It's Really Good, We Know It!

Tempero M.

J Natl Compr Canc Netw. 2017 Aug;15(8):973. doi: 10.6004/jnccn.2017.0141. No abstract available.

PMID:
28784856
50.

Reducing the Cost of Cancer Care: When Less Is More.

Tempero M.

J Natl Compr Canc Netw. 2017 Jul;15(7):853. doi: 10.6004/jnccn.2017.0125. No abstract available.

PMID:
28687571

Supplemental Content

Loading ...
Support Center